Form 424B3 Cellectar Biosciences,
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20250207/AN22G22CH22252Z2222R224ZBJTN92P26272
Filed on: February 7, 2025
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brookline Capital Markets Reinstates Cellectar Biosciences (CLRB) at Buy
- Cellectar publishes Phase 1 data on iopofosine I 131 in myeloma patients
- FORECLOSURE ACTIVITY POSTS ANNUAL INCREASE IN FIRST HALF OF 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
